BofA downgraded IGM Biosciences (IGMS) to Underperform from Neutral with a price target of 75c, down from $2, after the company released financial results in the form of a FY2024 10K, without an accompanying press release or management commentary. The company did not provide any update on strategic alternatives or the path forward, notes the analyst, who estimates that IGM will likely run out of cash sometime in 2027, even with sharply reduced expenditures and assuming future milestone payments from its early-stage Sanofi (SNY) collaboration.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue